SPOTLIGHT: Doubt cast on Fosamax link to jaw decay

by admin |

A new study by a Harvard dental professor may cast doubt on some claims that Merck's osteoporosis drug Fosamax caused some patients' jawbones to decay. The study shows that IV forms of the drug may have contributed to jaw disorders, but oral forms--which are far more commonly prescribed--actually reduced that risk. Report

Suggested Articles

fighting
Marketing

Keytruda's bladder cancer gene therapy rival wins in phase 3

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

by Angus Liu
Novartis headquarters
Pharma

FDA greenlights generics of Novartis' $3B MS star Gilenya

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

by Arlene Weintraub
armwrestle
Pharma

Gilead runs into pushback on HIV drug patent extension

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.

by Eric Sagonowsky